Skip to content

Checked

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

NCT05828511 on ClinicalTrials.gov

Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.

Status
Recruiting
Phase
Phase 1, Phase 2
Interventional
Planned enrollment
149
Participants, all sites
U.S. sites
13
In 8 states

Study details

Conditions
Multiple Myeloma
Sponsor
Regeneron Pharmaceuticals (Industry)
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Start
12/19/2023
Primary completion (expected)
11/02/2035
Last updated by sponsor
05/13/2026

Full eligibility rules, contacts and site names: NCT05828511 on ClinicalTrials.gov

Where the study has sites

Cities with at least one listed U.S. site. Some sites may not be enrolling yet.

  • California: Los Angeles, Orange
  • Colorado: Denver
  • Kentucky: Louisville
  • Michigan: Detroit
  • New Jersey: New Brunswick
  • New York: New York (2), Mineola, Stony Brook
  • North Carolina: Charlotte, Durham
  • Texas: Houston

More studies on the same topic

Frequently asked questions

What does recruiting mean?
Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
How do I join a clinical trial?
Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.

Source: ClinicalTrials.gov, National Library of Medicine · Last updated 05/13/2026